Skip to main content

Table 1 Characteristics of 103 advanced biliary tract cancer patients treated with gemcitabine and oxaliplatin (GEMOX) with or without erlotinib

From: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

  Study population
  GEMOX (n = 54) GEMOX plus erlotinib (n = 49)
Age, years   
  Median 62 (45–75) 59 (39–75)
Sex   
  Male 35 (64.8 %) 33 (67.3 %)
  Female 19 (35.2 %) 16 (32.7 %)
Primary site   
  Cholangiocarcinoma 38 (70.4 %) 38 (77.6 %)
  Gallbladder (GB) 16 (29.6 %) 11 (22.4 %)
Differentiation   
  Well/Moderate 33 (61.1 %) 26 (53.1 %)
  Poorly 21 (38.9 %) 23 (46.9 %)
Disease status   
  Recurrent 4 (7.4 %) 18 (36.7 %)
  Primarily metastatic 50 (92.6 %) 31 (63.3 %)
Liver only metastasis   
  Yes 10 (18.5 %) 8 (16.3 %)
  No 44 (81.5 %) 41 (83.7 %)
Number of metastatic sites   
  1 43 (79.6 %) 41 (83.7 %)
  2 ≤ 11 (20.4 %) 8 (16.3)
KRAS status   
  Mutant 3 (5.6 %) 5 (10.2 %)
  Wild 51 (94.4 %) 44 (89.8 %)
\